𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Chronic airflow obstruction and markers of systemic inflammation: Results from the BOLD study in Iceland

✍ Scribed by Sigurdur James Thorleifsson; Olof Birna Margretardottir; Gunnar Gudmundsson; Isleifur Olafsson; Bryndis Benediktsdottir; Christer Janson; A. Sonia Buist; Thorarinn Gislason

Book ID
116872488
Publisher
Elsevier Science
Year
2009
Tongue
English
Weight
177 KB
Volume
103
Category
Article
ISSN
0954-6111

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

A panel of multiple markers associated w
A panel of multiple markers associated with chronic systemic inflammation and the risk of atherogenesis is detectable in asthma and chronic obstructive pulmonary disease
✍ Tsu-Lan Wu; Pi-Yueh Chang; Kuo-Chien Tsao; Chien-Feng Sun; Lily L. Wu; James T. πŸ“‚ Article πŸ“… 2007 πŸ› John Wiley and Sons 🌐 English βš– 152 KB πŸ‘ 1 views

## Abstract Asthma and chronic obstructive pulmonary disease (COPD) are both lung diseases involving chronic inflammation of the airway. The injury is reversible in asthma whereas it is mostly irreversible in COPD. Both patients of asthma and COPD are known at risk for cardiovascular disease (CVD)

Subcutaneous Alemtuzumab in Fludarabine-
Subcutaneous Alemtuzumab in Fludarabine-Refractory Chronic Lymphocytic Leukemia: Clinical Results and Prognostic Marker Analyses From the CLL2H Study of the German Chronic Lymphocytic Leukemia Study Group
✍ Stilgenbauer, S.; Zenz, T.; Winkler, D.; Buhler, A.; Schlenk, R. F.; Groner, S.; πŸ“‚ Article πŸ“… 2009 πŸ› American Society of Clinical Oncology 🌐 English βš– 170 KB

## Purpose The phase II CLL2H trial evaluated safety and efficacy of subcutaneous alemtuzumab in patients with fludarabine-refractory chronic lymphocytic leukemia (CLL). Clinical and biologic markers were evaluated for their impacts on outcome. ## Patients and Methods One hundred nine patients